Obinutuzumab with mycophenolate mofetil for treating lupus nephritis (TA1131)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 12 February 2026
Belimumab for treating lupus nephritis (terminated appraisal) (TA806)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 13 July 2022
Anifrolumab for treating active autoantibody-positive systemic lupus erythematosus (terminated appraisal) (TA793)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 8 June 2022
Belimumab for treating active autoantibody-positive systemic lupus erythematosus (TA752)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 15 December 2021
Subcutaneous belimumab for treating systemic lupus erythematosus in children aged 5 to 17 [TSID11828]Status:Topic prioritisationProgramme:Technology appraisal guidanceExpected publication date: TBC
Obinutuzumab for treating serologically active extra-renal lupus [ID6670]Status:In development | In consultationProgramme:Technology appraisal guidanceConsultation end date: 23 March 2026Expected publication date: TBC